HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy. - HCMR (2222/0003)

niversity of Oxford0 个研究点目标入组 140 人开始时间: 待定最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Male or Female, aged 18-65
•Established diagnosis of HCM defined as unexplained LVH defined as any segment >= 15mm thick
•Signed informed consent
•Able (in the investigator's opinion) and willing to comply with all study requirements

•Uncontrolled hypertension as judged by the investigator
•Uncontrolled atrial fibrillation at time of enrollment
•Angiographically documented >50% coronary stenosis
•Prior septal myectomy or alcohol septal ablation
•Prior myocardial infarction
•Incessant ventricular arrhythmias
•Diabetes with end organ damage
•Stage IV/V chronic kidney disease (eGFR <30ml/min)
•Inability to tolerate MRI scanning (severe claustrophobia, inability to lie flat)
•Contraindications to CMR imaging (implantable devices or other metal implants, cranial aneurysm clips, metallic ocular foreign bodies, hypersensitivity to gadolinium)
•Female participant who is pregnant or lactating
•Malignancy or other serious medical condition expected to limit lifespan <5 years
•Any other significant disease or disorder which, in the opinion of the investigator, might influence the participant*s ability to participate in the study.
•Involvement in other studies thought to compromise resulting study data or the health of the participant
•Prior inclusion in the study of 5 members of the same immediate family.
•Inability to give informed consent

发起方